@article {45, editor = {,}, title = {The licensing of medicines in the UK}, volume = {47}, number = {4}, pages = {45--47}, year = {2009}, doi = {10.1136/dtb.2009.03.0012}, publisher = {British Medical Journal Publishing Group}, abstract = {Before a medicinal product* can be marketed in the UK, a marketing authorisation (formerly called a {\textquoteleft}product licence{\textquoteright}) is needed. Such an authorisation can be granted in the European Union (EU), via the European Medicines Agency (EMEA), European Commission (EC) and member state{\textquoteright}s competent authorities or, specifically in the UK, via the Medicines and Healthcare product Regulatory Agency (MHRA) on behalf of the UK licensing authority.2{\textendash}4 Also, a change to the authorisation is needed if the licensing status of a medicine is changed; for example, from a prescription-only medicine (POM) to a pharmacy medicine (P). Here we look at the procedures involved in the licensing of medicines (including herbal and homoeopathic products) for use in the UK.}, issn = {0012-6543}, URL = {https://dtb.bmj.com/content/47/4/45}, eprint = {https://dtb.bmj.com/content/47/4/45.full.pdf}, journal = {Drug and Therapeutics Bulletin} }